Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence

被引：2
作者：
Arévalo-Lorido J.C. [1 ]
Gómez J.C. [1 ]
Huelgas R.G. [2 ]
de Lucas D.G. [3 ]
Polo L.M. [4 ]
Aguilar J.M.V. [5 ]
Muñoz J.E. [6 ]
机构：
[1] Internal Medicine Department, Zafra County Hospital, Ctra Badajoz-Granada s/n, Zafra, 06300, Badajoz
[2] Internal Medicine Department, University Hospital of Málaga, Avda de Carlos Haya, s/n, Málaga
[3] Internal Medicine Department, “Costa del sol” Hospital, Autovía A7, Km 187, Marbella, 29603, Málaga
[4] Internal Medicine Department, University Hospital of Salamanca, Paseo de San Vicente 182, Salamanca
[5] Internal Medicine Department, University Hospital “Virgen del Rocio”, Av. Manuel Siurot, s/n, Sevilla
[6] Internal Medicine Department, “Marina Baixa” Hospital, Avda, Alcalde En Jaume Botella Mayor, s/n, La Vila Joiosa, 03570, Alicante
来源：
High Blood Pressure & Cardiovascular Prevention | 2018年 / 25卷 / 4期
关键词：
Ambulatory blood pressure monitoring; Diabetes; Glucagon-like peptide-1 receptor agonist; Sodium-glucose cotransporter 2 inhibitor;
D O I：
10.1007/s40292-018-0280-1
中图分类号：
学科分类号：
摘要：
Introduction: Patients with type 2 diabetes mellitus (T2DM) often have numerous cardiovascular risk factors, among which hypertension. Aim: To evaluate the blood pressure variations among patients treated with a combination of a sodium-glucose cotransporter 2 inhibitor (iSGLT-2) and a glucagon-like peptide-1 receptor agonist (GLP-1ra). Methods: We analyze 17 patients treated with this combination to quantify the changes on blood pressure by ambulatory blood pressure monitoring at baseline and at three and 6 months follow-up. Results: We observed a decrease of HbA1c levels (p = 0.004) at six months follow-up, a decrease in mean 24 h systolic blood pressure [from 124 (11) mmHg to 123 (4.75) mmHg, p = 0.04] and in both, mean waking and sleeping systolic blood pressure, being greater the reduction in the sleeping time [118 (20) mmHg to 111 (20) mmHg, p = 0.004]. Conclusion: The effect of a combination therapy of an iSGLT-2 and a GLP-1ra on blood pressure in a real-world setting, may have summative effects especially in SBP. © 2018, Springer Nature Switzerland AG.
引用
收藏
页码：417 / 420
页数：3
相关论文
共 10 条
  • [1] Matheus A.S., Tannus L.R., Cobas R.A., Palma C.C., Negrato C.A., Gomes M.B., Impact of diabetes on cardiovascular disease: an update, Int J Hypertens., 2013, (2013)
  • [2] Kiselev A.R., Posnenkova O.M., Belova O.A., Romanchuk S.V., Popova Y.V., Prokhorov M.D., Et al., Impact of clinical factors on the achievement of target blood pressure in hypertensive patients from Ivanovo region of Russia: data of 2015, High Blood Press Cardiovasc Prev., 24, pp. 425-435, (2017)
  • [3] Tikkanen I., Narko K., Zeller C., Green A., Salsali A., Broedl U.C., Et al., Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension, Diabetes Care, 38, pp. 420-428, (2015)
  • [4] Heerspink H.J., de Zeeuw D., Wie L., Leslie B., List J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes, Diabetes Obes Metab, 15, pp. 853-862, (2013)
  • [5] Townsend R.R., Machin I., Ren J., Trujillo A., Kawaguchi M., Vijapurkar U., Et al., Reductions in Mean 24-Hour Ambulatory Blood Pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension, J Clin Hypertens (Greenwich)., 18, pp. 43-52, (2016)
  • [6] Fonseca V.A., Deuries J.H., Henry R.R., Donsmark M., Thomsen H.F., Plutzky J., Reduction in systolic blood pressure with Liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials, J Diabetes Complications, 28, pp. 399-405, (2014)
  • [7] Kumarathurai P., Anholm C., Fabricius-Bjerre A., Nielsen O.W., Kristiansen O., Madsbad S., Et al., Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized double-blind, placebo-controlled, crossover study, J Hypertens, 35, pp. 1070-1078, (2017)
  • [8] Ferdinand K.C., White W.B., Calhon D.A., Lonn E.M., Sajer P.T., Brunelle R., Et al., Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus, Hypertension, 64, pp. 731-737, (2014)
  • [9] Lundkvist P., Pereira M.J., Katsogiannos P., Sjostrom C.D., Johnsson E., Eriksson J.W., Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in body weight, glycaemia and blood pressure over 1 year, Diabetes Obes Metab, 19, pp. 1276-1288, (2017)
  • [10] Ludvik B., Frias J.P., Tinahones F.J., Wainstein J., Jiang H., Robertson K.E., Et al., Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol., 6, pp. 370-381, (2018)
1